ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2636

Comparison of Arterial Health in Patients with Rheumatoid Arthritis to a Population-Based Cohort

Caroline Ball1, John M. Davis III2, Cynthia S. Crowson3, Iftikhar Kullo4, Eric L. Matteson5 and Rekha Mankad6, 1Internal Medicine, Mayo Clinic, Rochester, MN, 2Division of Rheumatology, Mayo Clinic, Rochester, MN, 3Health Sciences Research, Mayo Clinic, Rochester, MN, 4Department of Internal Medicine, Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 6Cardiovascular Diseases, Mayo Clinic, Rochester, MN

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Clinical Aspects Poster Session III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Title: Comparison of Arterial Health in Patients with
Rheumatoid Arthritis to a Population-based Cohort

Background/Purpose: Patients with rheumatoid arthritis
(RA) have increased risk of cardiovascular disease (CVD). Vascular stiffness is
associated with increased cardiovascular risk in the general population. We aim
to characterize the differences in arterial health, including vascular
stiffness and endothelial function between patients with RA and no history of
CVD and a population-based cohort of non-RA patients without a known history of
CVD or RA.  

 

Methods: A set of arterial health tests were carried
out in patients with RA who were seen in our institution’s Cardio-Rheumatology Clinic
as part of a cardiovascular risk assessment. Assessment included 2-D carotid
artery ultrasound, brachial artery reactivity, and arterial tonometry. Data
from these patients were compared to normative data from the institution’s
cardiovascular healthcare clinic.  Each patient with RA was matched on age and
sex to 10 subjects from the comparison cohort. Diagnosis of RA was made by rheumatologists
according to the 2010 American College of Rheumatology/ European League Against
Rheumatism criteria. Comparisons between cohorts were performed using conditional
logistic regression.

Results:  The study cohort included 28 patients with RA
(mean age: 58.1 [SD:10.4] years; 82% female) compared to 280 controls (mean
age: 58.4 [SD:9.7] years; 82% female). Flow-mediated dilation (FMD) was higher
in the patients with RA (8.7±6.3 vs 6.2±4.9, p=0.014; Table) than controls. Hyperemic
flow was marginally higher in the patients with RA (458±255 vs 403±169, p=0.067).
Among our RA cohort, treatments included methotrexate in 61%, corticosteroids
in 39% and biologics in 54% at the time of arterial health studies.

 

Conclusion:  

In subjects without a history of CVD, vascular stiffness is
similar in patients with treated RA compared with subjects without RA. 
Patients with RA show a trend toward decreased augmentation pressure,
augmentation index and pulse wave velocity, consistent with increased arterial
stiffness.  Flow-mediated dilation was increased in patients with RA,
suggesting better endothelial function. Hyperemic response was similar in both
cohorts. It is possible that endothelial function in this population is
affected by RA therapies. These measures of arterial stiffness may also have
prognostic values for prediction of risk for CVD and lead to more targeted
prevention strategies to reduce this risk in this population that is already at
higher risk for CVD.

  

Table

 

Control

N=280

RA Patients

N=28

p-value

Augmentation Pressure (mmHg)

14.6 ± 7.5

14.1 ± 7.5

0.65

Aortic Pulse Pressure (mmHg)

43.2 ± 14.3

44.7 ± 16.5

0.59

Augmentation Index (%)

32.5 ± 10.1

30.2 ± 10.6

0.23

Pulse Wave Velocity (m/s)

9.5 ± 2.8

8.7 ± 2.0

0.14

Brachial Artery Diameter (mm)

3.5 ± 0.7

3.4 ± 0.8

0.20

Basal Flow (mL/min)

59.0 ± 62.6

71.4 ± 61.6

0.30

Hyperemic Flow (mL/min)

403.4 ± 169.2

458.3 ± 254.6

0.067

Flow Mediated Dilation (%)

6.2 ± 4.9

8.7 ± 6.3

0.014

Hyperemic flow response

0.15 ± 0.12

0.15 ± 0.08

0.75

 


Disclosure: C. Ball, None; J. M. Davis III, None; C. S. Crowson, None; I. Kullo, Fukuda, 2; E. L. Matteson, None; R. Mankad, None.

To cite this abstract in AMA style:

Ball C, Davis JM III, Crowson CS, Kullo I, Matteson EL, Mankad R. Comparison of Arterial Health in Patients with Rheumatoid Arthritis to a Population-Based Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/comparison-of-arterial-health-in-patients-with-rheumatoid-arthritis-to-a-population-based-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-arterial-health-in-patients-with-rheumatoid-arthritis-to-a-population-based-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology